uBiome Valuation, Funding & Investors

PrognomiQ is a proteomics company generating multi-omics datasets for early disease detection. Headquartered in San Francisco, it maps proteomes alongside genomics and metabolomics to uncover biomarkers for cancer and neurodegenerative disorders. PrognomiQ's platform powered the largest human plasma proteome map published in 2023.

MedGenome is a Bangalore-based genomics company offering next-generation sequencing diagnostics and research services for cancer, metabolic, cardiac, and rare diseases. The firm operates CLIA-certified labs in the United States and India, processing samples for over 500 hospitals and research institutions. Its platform integrates bioinformatics with population-scale data from South Asian genomes, supporting drug discovery partnerships with AstraZeneca and Bristol Myers Squibb in precision medicine initiatives.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.

Genome Medical is a national telegenomics company providing virtual genetic care through its network of specialists and Genome Care Delivery platform. It assists healthcare providers and patients in interpreting genetic tests for disease risk assessment, diagnosis acceleration, treatment decisions, and cost reduction in everyday care.

Geneoscopy is a St. Louis-based diagnostics company that offers non-invasive stool RNA tests for colorectal cancer screening using computational biology. Its ColoSense assay detects gene expression changes in human RNA extracted from stool, achieving 92 percent sensitivity for CRC and 90 percent for advanced adenomas in pivotal trials. Geneoscopy expands its platform to other gastrointestinal diseases including IBD and pancreatic cancer screening.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Hexagon Bio is a Menlo Park-based biotechnology company engineering small molecule therapeutics from fungal genomes. Its platform merges data science and synthetic biology to identify drug candidates targeting unmet needs in infectious diseases and oncology through natural product optimization.

Valo Health is a Boston-headquartered biotech firm that integrates multimodal human data into its Opal Computational Platform for drug discovery. The platform analyzes real-world evidence, clinical, and molecular datasets to advance therapies in cardiovascular, metabolic, renal, oncology, and neurodegenerative areas. Valo maintains offices in Lexington and New York City alongside its Boston base. Launched in 2018 by Flagship Pioneering, it collaborates with AstraZeneca on heart failure programs and Bayer on cardiovascular targets. The company processes petabytes of data to nominate drug candidates and optimize trials.